Blog

Please reserve for your seat at the below eventbrite link for free. https://www.eventbrite.com/e/novel-therapeutic-targets-in-both-breast-and-kidney-cancers-tickets-119195604261 Hypoxia is associated with resistance towards radiation and chemotherapy. As tumors grow, they can sense the oxygen tension and reprogram critical pathways that are important for cancer cell survival and therapy resistance. One of examples is through upregulation of hypoxia inducible factorRead more

Yichang, Hubei, Aug 13, 2020 – A seminar on preclinical R&D strategic cooperation was held between Medicilon. INC (Stock Code: 688202. SH) and Yichang Humanwell Pharmaceutical CO.LTD (Stock Code: 600079. SH). During the meeting, the two companies discussed the vision of cooperation in the future, hoping to strengthen the relationship, jointly promote the research andRead more

Medicilon will exhibit the ACS Fall 2020 Virtual Meeting & Expo from Aug 17-20.  Please visit https://calendly.com/fywang to schedule a 1-on-1 meeting with our VP of Business Development, Dr. Frank Wang, for our chemistry study.  We look forward to see you.Read more

On July 20, 2020, DAC Biotech’s new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue.Read more

Chuansha, Shanghai, June 29, 2020. — Convalife and Medicilon signed a strategic pact, initiating a long-term cooperation between the two companies. Based on previous cooperation and the mutual trust, Medicilon and Convalife achieved consensus on the partnership that Medicilon will assist Convalife in new drug development utilizing its integrated pharmaceutical R&D service platform. According toRead more

Due to the COVID-19 pandemic, the 2020 SAPA Healthcare Investment Forum & Roadshow will be divided in 2 parts.  Part I will be hosted as a virtual digital session on June 20, 2020 and Part II will be hosted in conjunction with the SAPA Annual Conference on the weekend of Oct 3rd this year.  MedicilonRead more

Heganding comes in 100-mg tablets. It’s a treatment for chronic Heptitis B adult patients with ALT rising, active virus replicating and liver decompensation. During the evaluation project, Medicilon’s CMC and management team utilized innovative technology and comprehensive understanding of related guidance and regulations to contribute to success of the consisteny evaluation with biowaiver.Read more

Congratualtions to Medicilon’s partner, Bio-Thera, on obtaining NMPA’s approval of clinical trials of BAT1308. On May 27th, 2020, Bio-Thera Solutions, Ltd, annouced the approval of clinical trials on BAT 1308, an anti PD-1 monoclonal antibody. Medicilon participated in BAT 1308’s preclinical study by conducting the In Vivo PK test and safety evaluation tests under GLP.Read more

Good News! Led by Dr. CHUN-LIN CHEN, the founder and CEO of Shanghai Medicilon Inc., the entreprenuer team in Medicilon received the “Most Improved in the Science and Technology” award presented by Pudong New Area.Read more

On May 21st 2020, the Deputy Mayor of Haining Municipal Government Yang Wenhua and his team visited Medicilon for the research. Dr. Chunlin Chen, Founder & CEO of Medicilon, accompanied the research and report. During the visiting for the research, Dr. Chen introduced the 16 years of development history of Medicilon, a one-stop preclinical newRead more